{"symbol":"ABBV","fiscalQuarter":"Q2-2026","reportDate":"2026-07-30","reportTime":"BMO","status":"upcoming","company":{"name":"AbbVie Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/ABBV/earnings/Q2-2026","preBrief":{"companySnapshot":"AbbVie Inc. is a global biopharmaceutical company focused on developing advanced therapies for complex diseases. With a market cap of $365 billion, it plays a significant role in the healthcare sector, particularly in immunology, oncology, and neuroscience.","keyMetrics":[{"name":"Earnings Per Share (EPS)","why":"EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.","consensus":"N/A"},{"name":"Revenue Growth","why":"Revenue growth reflects the company's ability to expand its market share and product offerings, crucial for future investments.","consensus":"N/A"},{"name":"Pipeline Progress","why":"Updates on the drug pipeline can indicate future revenue potential and market competitiveness.","consensus":"N/A"}],"lastQuarterRecap":{"summary":"In Q1 2026, AbbVie reported an EPS of $2.65, slightly beating estimates. The stock reacted positively, gaining 3.14% the following day.","promises":["Commitment to advancing its pipeline of new therapies.","Focus on expanding market presence in key therapeutic areas.","Continued investment in research and development."]},"wallStreetExpectations":{"summary":"Investors are cautiously optimistic about AbbVie's upcoming earnings, expecting continued growth in EPS and potential updates on its drug pipeline.","bullCase":"If AbbVie can demonstrate strong revenue growth and positive pipeline developments, it could lead to a significant stock price increase.","bearCase":"Conversely, if the company reports disappointing earnings or setbacks in its drug pipeline, it may lead to a decline in stock value."},"optionsSignal":{"impliedMove":"3.63%","context":"The options market is pricing in a move of about 3.63%, indicating that investors expect some volatility around the earnings announcement."},"earningsTrackRecord":[{"quarter":"Q1-2026","epsSurprise":"+1.30%","reaction":"+3.14%"},{"quarter":"Q4-2025","epsSurprise":"+2.03%","reaction":"-3.79%"},{"quarter":"Q3-2025","epsSurprise":"+4.91%","reaction":"-4.45%"},{"quarter":"Q2-2025","epsSurprise":"-8.39%","reaction":"-0.15%"},{"quarter":"Q1-2025","epsSurprise":"+2.93%","reaction":"+3.15%"}],"pivotalQuestions":[{"question":"What will be the EPS for Q2-2026?","whyItMatters":"EPS is a critical measure of profitability, and any significant deviation from expectations could impact investor sentiment."},{"question":"What updates will be provided on the drug pipeline?","whyItMatters":"Insights into the pipeline can significantly influence future revenue projections and investor confidence."}],"thesisBreakLevels":{"bullTrigger":"An EPS of $2.70 or higher would confirm strong profitability and investor confidence.","bearTrigger":"An EPS below $2.60 could signal potential issues in profitability and growth.","context":"The market is debating AbbVie's ability to maintain its growth trajectory amidst competitive pressures and pipeline developments."},"scenarioPlaybook":{"beatAndRaise":"If AbbVie beats expectations, history suggests a potential stock increase of around 1.78%, confirming strong operational performance.","inLineCautious":"If results are in line with expectations, the stock may experience muted movement as investors await further guidance.","miss":"A miss could lead to a decline of about 0.15%, reflecting investor disappointment and concerns about future growth."},"whatTheStreetIsMissing":{"thesis":"The Street may be underestimating the potential for AbbVie’s new therapies to drive significant revenue growth, especially in emerging markets.","supportingPoints":["Historical data shows a strong track record of beating EPS estimates, suggesting potential upside.","Recent insider selling may indicate a strategic shift rather than lack of confidence in the company's future.","Options pricing suggests a more conservative outlook than what historical performance would imply."],"riskToConsensus":"If pipeline developments show promising results, it could significantly alter the growth narrative."},"whatToListenFor":["Any specific guidance on EPS for Q2-2026.","Updates on the status of key drugs in the pipeline.","Comments on market expansion strategies.","Insights into competitive pressures in the biotechnology sector.","Management's outlook on future revenue growth."],"metaDescription":"AbbVie (ABBV) reports Q2 2026 earnings July 30. Investors are watching for EPS guidance and pipeline updates."}}